Sarepta stock closed down more than forty four percentage.
Sarepta is seeking out extended acclaim for eteplirsen to treat a subset of patients with Duchenne muscular dystrophy (DMD).
FDA workforce reviewers on Thursday reiterated their soreness with the drug — elevating issuessurrounding the drug’s trials, its effectiveness, and the corporation‘s statistical analysis.
Biotech shares so terrible they’ll be accurate: Technician
Scientists in January highlighted comparable issues in advance of a scheduled meeting of an impartial panel of experts to the FDA. however, this meeting was postponed because of an inclement weather forecast for Washington.
“At this point … you are essentially giving up all that desire going returned to mid-January,” Mike Bailey, director of research and chair at FBB Capital partners, informed CNBC.
entering Thursday trading, the inventory was down nearly 50 percent for 2016.